A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk

Simply Wall St.

Apr 07

Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2625981967"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625981967\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625981967?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-04-07 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625981967","market":"nz","top_or_hot":-1,"title":"A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk","media":"Simply Wall St.","content":"<div>\n<p>Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/a-look-at-scholar-rock-srrk-valuation-after-apitegromab-bla\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Scholar Rock (SRRK) Valuation After Apitegromab BLA Resubmission And Reduced Regulatory Risk\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-07 11:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/a-look-at-scholar-rock-srrk-valuation-after-apitegromab-bla><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/a-look-at-scholar-rock-srrk-valuation-after-apitegromab-bla\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/a-look-at-scholar-rock-srrk-valuation-after-apitegromab-bla","article_id":"2625981967","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/a-look-at-scholar-rock-srrk-valuation-after-apitegromab-bla","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625981967","pubTimestamp":1775531634,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US based fill finish site.\nSee our latest analysis for Scholar Rock Holding.\nThe BLA resubmission appears to have kept attention on Scholar Rock, with a 7 day share price return of 13.3% and an 18.16% 90 day share price return. The 1 year total shareholder return of 87.44% points to strong momentum...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SRRK":"Scholar Rock Holding Corp"},"translate_title":"Apitegromab BLA重新提交和监管风险降低后Scholar Rock(SRRK)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SRRK":1.5},"content_text":"Scholar Rock Holding (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following alignment with regulators on facility remediation and the addition of a second US based fill finish site. See our latest analysis for Scholar Rock Holding. The BLA resubmission appears to have kept attention on Scholar Rock, with a 7 day share price return of 13.3% and an 18.16% 90 day share price return. The 1 year total shareholder return of 87.44% points to strong momentum over a longer horizon. If this kind of catalyst driven move has your attention, it can be worth widening your watchlist using the 37 healthcare AI stocks. With the share price already up strongly over 1 and 3 years and trading at a discount to the average analyst price target, the key question now is whether Scholar Rock is still undervalued or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 11.4% Undervalued Scholar Rock’s most followed narrative pegs fair value at $55.07, above the last close of $48.81. This frames the recent rally as only part of the story.  Scholar Rock’s strengthening of its commercial and supply infrastructure, including a 50 country operating build out, a second fill finish facility and a large home infusion and specialty pharmacy network, is aimed at supporting broad access and could influence both revenue scale and net margins as fixed launch investments are spread over a larger sales base.  Read the complete narrative. Curious what justifies pricing in a business that currently reports no revenue yet is modeled with rising margins and premium earnings multiples? The narrative leans heavily on future revenue ramp, ongoing loss making forecasts and a valuation multiple far above typical biotech peers. Want to see which assumptions have to hold for the $55.07 fair value to make sense. Result: Fair Value of $55.07 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this depends on apitegromab clearing regulatory inspections on time and launch spending not outpacing uptake, which could otherwise challenge the 11.4% undervalued case. Find out about the key risks to this Scholar Rock Holding narrative. Next Steps With sentiment clearly split between risks and rewards, it makes sense to check the numbers yourself and move quickly to shape your own view using the 2 key rewards and 4 important warning signs. Looking for more investment ideas? If Scholar Rock is on your radar, do not stop there. Broaden your opportunity set with focused stock ideas built from clear fundamentals and risk profiles.  Spot potential value opportunities before the crowd by scanning companies that trade below their assessed worth using the 62 high quality undervalued stocks. Prioritise financial strength by zeroing in on businesses with robust balance sheets and solid fundamentals through the solid balance sheet and fundamentals stocks screener (40 results). Hunt for off the radar opportunities by checking a screener containing 25 high quality undiscovered gems that surfaces quality names many investors may be overlooking.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}